Dual delivery of an antibiotic and a growth factor addresses both the microbiological and biological challenges of contaminated bone fractures

Expert Opinion on Drug Delivery

Volumn 8, Issue 12, 2011, Pages 1555-1569

  Wenke, Joseph C ^a   Guelcher, Scott A ^b,c  

^a US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibiotic; Bone; Bone morphogenetic protein; Dual purpose; Graft; Growth factor; Infection; Scaffold; Tissue engineering

Indexed keywords

ANTIBIOTIC AGENT; GENTAMICIN BONE CEMENT; GROWTH FACTOR; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

BACTERIAL COLONIZATION; BACTERIAL SURVIVAL; BIOFILM; BONE GRAFT; BONE INFECTION; BONE REGENERATION; CELL DIFFERENTIATION; DEBRIDEMENT; DRUG DELIVERY SYSTEM; FRACTURE; FRACTURE FIXATION; FRACTURE HEALING; FRACTURE NONUNION; HUMAN; OPEN FRACTURE; OSTEOBLAST; REVIEW; SUSTAINED DRUG RELEASE; TISSUE ENGINEERING; TREATMENT OUTCOME; VASCULARIZATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BONE MORPHOGENETIC PROTEIN 2; BONE TRANSPLANTATION; FRACTURES, BONE; FRACTURES, OPEN; HUMANS; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 81855167468     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.628655     Document Type: Review

References (123)

1. Seeherman H, Wozney JM. Delivery of bone morphogenetic proteins for orthopedic tissue regeneration. Cytokine Growth Factor Rev 2005;16:329-45 (Pubitemid 40910322)
2. Haidar ZS, Hamdy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part B: delivery systems for BMPs in orthopaedic and craniofacial tissue engineering. Biotechnol Lett 2009;31:1825-35
3. Haidar ZS, Hamdy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: current challenges in BMP delivery. Biotechnol Lett 2009;31:1817-24
4. Li RH, Wozney JM. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol 2001;19:255-65 (Pubitemid 32537763)
5. Jones AL, Bucholz RW, Bosse MJ, et al. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 2006;88:1431-41
6. Gristina AG, Naylor P, Myrvik Q. Infections from biomaterials and implants: a race for the surface. Med Prog Technol 1988;14:205-24 (Pubitemid 19224293)
7. Stewart RL, Cox JT, Volgas D, et al. The use of a biodegradable, load-bearing scaffold as a carrier for antibiotics in an infected open fracture model. J Orthop Trauma 2010;24:587-91
8. Zheng Z, Yin W, Zara JN, et al. The use of BMP-2 coupled - Nanosilver-PLGA composite grafts to induce bone repair in grossly infected segmental defects. Biomaterials 2010;31:9293-300
9. Guelcher SA, Brown KV, Li B, et al. Dual-purpose bone grafts improve healing and reduce infection. J Orthop Trauma 2011;25:477-82
10. Reves BT, Bumgardner JD, Cole JA, et al. Lyophilization to improve drug delivery for chitosan-calcium phosphate bone scaffold construct: a preliminary investigation. J Biomed Mater Res B Appl Biomater 2009;90:1-10
11. Bosse MJ, Mac Kenzie EJ, Kellam JF, et al. An analysis of outcomes of reconstruction or amputation after leg-threatening injuries. N Engl J Med 2002;347:1924-31 (Pubitemid 35429922)
12. Harris AM, Althausen PL, Kellam J, et al. Complications following limb-threatening lower extremity trauma. J Orthop Trauma 2009;23:1-6
13. Johnson EN, Burns TC, Hayda RA, et al. Infectious complications of open type III tibial fractures among combat casualties. Clin Infect Dis 2007;45:409-15 (Pubitemid 47204454)
14. Okike K, Bhattacharyya T. Trends in the management of open fractures. A critical analysis. J Bone Joint Surg Am 2006;88:2739-48 (Pubitemid 44901964)
15. Mc Laren AC. Alternative materials to acrylic bone cement for delivery of depot antibiotics in orthopaedic infections. Clin Orthop Relat Res 2004;427:101-6 (Pubitemid 39362838)
16. Swiontkowski MF, Aro HT, Donell S, et al. Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies. J Bone Joint Surg Am 2006;88:1258-65 (Pubitemid 43837120)
17. Keeling JJ, Gwinn DE, Tintle SM, et al. Short-term outcomes of severe open wartime tibial fractures treated with ring external fixation. J Bone Joint Surg Am 2008;90:2643-51
18. Patzakis MJ, Wilkins J. Factors influencing infection rate in open fracture wounds. Clin Orthop Relat Res 1989 Jun;(243):36-40. (Pubitemid 19165361)
19. Murray CK, Obremskey WT, Hsu JR, et al. Prevention of Combat-related Infections Guidelines Panel. Prevention of infections associated with combat-related extremity injuries. J Trauma 2011;71:S235-57
20. Kanellakopoulou K, Giamaraellos-Bourboulis E. Carrier systems for the local delivery of antibiotics in bone infections. Drugs 2000;59:1223-32 (Pubitemid 30410141)
21. Beardmore AA, Brooks DE, Wenke JC, Thomas DB. Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute. J Bone Joint Surg Am 2005;87:107-12 (Pubitemid 40094145)
22. Gitelis S, Brebach GT. The treatment of chronic osteomyelitis with a biodegradable antibiotic-impregnated implant. J Orthop Surg (Hong Kong) 2002;10:53-60 (Pubitemid 35332424)
23. Mc Kee MD, Wild LM, Schemitsch EH, Waddell JP. The use of an antibiotic-impregnated, osteoconductive, bioabsorbable bone substitute in the treatment of infected long bone defects: early results of a prospective trial. J Orthop Trauma 2002;16:622-7 (Pubitemid 35214851)
24. Helgeson MD, Potter BK, Tucker CJ, et al. Antibiotic-impregnated calcium sulfate use in combat-related open fractures. Orthopedics 2009;32:323
25. Kirker-Head C. Potential applications and delivery strategies for bone morphogenetic proteins. Adv Drug Deliv Rev 2000;43:65-92
26. Uludag H, Gao T, Porter T, et al. Delivery systems for BMPS: factors contributing to the protein retention at an application site. J Bone Joint Surg 2001;83-A:S128-35
27. Cho TJ, Gerstenfeld LC, Einhorn TA. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res 2002;17:513-20 (Pubitemid 34171766)
28. Geiger M, Li RH, Friess W. Collagen sponges for bone regeneration with rh BMP-2. Adv Drug Deliv Rev 2003;55:1613-29 (Pubitemid 37420006)
29. Brown KV, Li B, Guda T, et al. Improving bone formation in a rat femur segmental defect by controlling bone morphogenetic protein-2 release. Tissue Eng Part A 2011;17:1735-46
30. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2008;2:81-96
31. Mano JF, Reis RL. Osteochondral defects: present situation and tissue engineering approaches. J Tissue Eng Regen Med 2007;1:261-73
32. Aebli N, Stich H, Schawalder P, et al. Effects of bone morphogenetic protein-2 and hyaluronic acid on the osseointegration of hydroxyapatite-coated implants: an experimental study in sheep. J Biomed Mater Res A 2005;73:295-302 (Pubitemid 40664295)
33. Eckardt H, Christensen KS, Lind M, et al. Recombinant human bone morphogenetic protein 2 enhances bone healing in an experimental model of fractures at risk of non-union. Injury 2005;36:489-94 (Pubitemid 40332331)
34. Arosarena OA, Collins WL. Bone regeneration in the rat mandible with bone morphogenetic protein-2: a comparison of two carriers. Otolaryngol Head Neck Surg 2005;132:592-7 (Pubitemid 40460890)
35. Saito A, Suzuki Y, Kitamura M, et al. Repair of 20-mm long rabbit radial bone defects using BMP-derived peptide combined with an alpha-tricalcium phosphate scaffold. J Biomed Mater Res A 2006;77:700-6 (Pubitemid 47233551)
36. Park DJ, Choi BH, Zhu SJ, et al. Injectable bone using chitosan-alginate gel/mesenchymal stem cells/BMP- 2 composites. J Craniomaxillofac Surg 2005;33:50-4
37. Jung RE, Schmoekel HG, Zwahlen R, et al. Platelet-rich plasma and fibrin as delivery systems for recombinant human bone morphogenetic protein-2. Clin Oral Implants Res 2005;16:676-82 (Pubitemid 43951429)
38. Kirker-Head C, Karageorgiou V, Hofmann S, et al. BMP-silk composite matrices heal critically sized femoral defects. Bone 2007;41:247-55 (Pubitemid 47001819)
39. Miyamoto S, Takaoka K, Okada T, et al. Evaluation of polylactic acid homopolymers as carriers for bone morphogenetic protein. Clin Orthop Relat Res 1992;278:274-85
40. Saito N, Takaoka K. New synthetic biodegradable polymers as BMP carriers for bone tissue engineering. Biomaterials 2003;24:2287-93 (Pubitemid 36434047)
41. Mayer MH, Hollinger JO, Ron E, Wozney J. Repair of alveolar clefts in dogs with recombinant bone morphogenetic protein and poly(alpha-hydroxy acid). Plast Reconstr Surg 1996;98:247-59 (Pubitemid 26250473)
42. Shimazu C, Hara T, Kinuta Y, et al. Enhanced vertical alveolar bone augmentation by recombinant human bone morphogenetic protein-2 with a carrier in rats. J Oral Rehabil 2006;33:609-18 (Pubitemid 44006088)
43. Young S, Patel ZS, Kretlow JD, et al. Dose effect of dual delivery of vascular endothelial growth factor and bone morphogenetic protein-2 on bone regeneration in a rat critical-size defect model. Tissue Eng Part A 2009;15:2347-62
44. Kempen DH, Kruyt MC, Lu L, et al. Effect of autologous bone marrow stromal cell seeding and bone morphogenetic protein-2 delivery on ectopic bone formation in a microsphere/ poly(propylene fumarate) composite. Tissue Eng Part A 2009;15:587-94
45. Chu TM, Warden SJ, Turner CH, Stewart RL. Segmental bone regeneration using a load-bearing biodegradable carrier of bone morphogenetic protein-2. Biomaterials 2007;28:459-67 (Pubitemid 44602234)
46. Kolambkar YM, Dupont KM, Boerckel JD, et al. An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects. Biomaterials 2011;32:65-74
47. Boerckel JD, Kolambkar YM, Dupont KM, et al. Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials 2011;32:5241-51
48. Rey-Rico A, Silva M, Couceiro J, et al. Osteogenic efficiency of in situ gelling poloxamine systems with and without bone morphogenetic protein-2. Eur Cell Mater 2011;21:317-40
49. Kim HK, Shim WS, Kim SE, et al. Injectable in situ-forming p H/thermo- sensitive hydrogel for bone tissue engineering. Tissue Eng Part A 2009;15:923-33
50. Stephan SJ, Tholpady SS, Gross B, et al. Injectable tissue-engineered bone repair of a rat calvarial defect. Laryngoscope 2010;120:895-901
51. Santos EM, Radin S, Ducheyne P. Sol-gel derived carrier for the controlled release of proteins. Biomaterials 1999;20:1695-700 (Pubitemid 29393124)
52. Viitala R, Jokinen M, Rosenholm JB. Mechanistic studies on release of large and small molecules from biodegradable Si O2. Int J Pharm 2007;336:382-90 (Pubitemid 46670657)
53. Adams CS, Antoci V Jr, Harrison G, et al. Controlled release of vancomycin from thin sol-gel films on implant surfaces successfully controls osteomyelitis. J Orthop Res 2009;27:701-9
54. Radin S, Ducheyne P. Controlled release of vancomycin from thin sol-gel films on titanium alloy fracture plate material. Biomaterials 2007;28:1721-9 (Pubitemid 46080466)
55. Noel SP, Courtney HS, Bumgardner JD, Haggard WO. Chitosan sponges to locally deliver amikacin and vancomycin: a pilot in vitro evaluation. Clin Orthop Relat Res 2010;468:2074-80
56. Aughenbaugh W, Radin S, Ducheyne P. Silica sol-gel for the controlled release of antibiotics. II. The effect of synthesis parameters on the in vitro release kinetics of vanomycin. J Biomed Mater Res 2001;57:321-6
57. Radin S, Ducheyne P, Kamplain T, Tan BH. Silica sol-gel for the controlled release of antibiotics. I. Synthesis, characterization, and in vitro release. J Biomed Mater Res 2001;57:313-20 (Pubitemid 32988512)
58. Lee EJ, Jun SH, Kim HE, et al. Silica xerogel-chitosan nano-hybrids for use as drug eluting bone replacement. J Mater Sci Mater Med 2010;21:207-14
59. Thakur RA, Florek CA, Kohn J, Michniak BB. Electrospun nanofibrous polymeric scaffold with targeted drug release profiles for potential application as wound dressing. Int J Pharm 2008;364:87-93
60. Feng K, Sun H, Bradley MA, et al. Novel antibacterial nanofibrous PLLA scaffolds. J Control Release 2010;146:363-9
61. Ambrose CG, Gogola GR, Clyburn TA, et al. Antibiotic microspheres: preliminary testing for potential treatment of osteomyelitis. Clin Orthop Relat Res 2003;415:279-85 (Pubitemid 37329065)
62. Aishwarya S, Mahalakshmi S, Sehgal PK. Collagen-coated polycaprolactone microparticles as a controlled drug delivery system. J Microencapsul 2008;25:298-306 (Pubitemid 352025006)
63. Virto MR, Elorza B, Torrado S, et al. Improvement of gentamicin poly(D,L-lactic-co-glycolic acid) microspheres for treatment of osteomyelitis induced by orthopedic procedures. Biomaterials 2007;28:877-85 (Pubitemid 44667024)
64. Radin S, Chen T, Ducheyne P. The controlled release of drugs from emulsified, sol gel processed silica microspheres. Biomaterials 2009;30:850-8
65. Adams SB Jr, Shamji MF, Nettles DL, et al. Sustained release of antibiotics from injectable and thermally responsive polypeptide depots. J Biomed Mater Res B Appl Biomater 2009;90:67-74
66. Peng KT, Chen CF, Chu IM, et al. Treatment of osteomyelitis with teicoplanin-encapsulated biodegradable thermosensitive hydrogel nanoparticles. Biomaterials 2010;31:5227-36
67. Ferraz MP, Mateus AY, Sousa JC, Monteiro FJ. Nanohydroxyapatite microspheres as delivery system for antibiotics: release kinetics, antimicrobial activity, and interaction with osteoblasts. J Biomed Mater Res A 2007;81:994-1004 (Pubitemid 46835096)
68. Kundu B, Soundrapandian C, Nandi SK, et al. Development of new localized drug delivery system based on ceftriaxone-sulbactam composite drug impregnated porous hydroxyapatite: a systematic approach for in vitro and in vivo animal trial. Pharm Res 2010;27:1659-76
69. El-Ghannam A, Jahed K, Govindaswami M. Resorbable bioactive ceramic for treatment of bone infection. J Biomed Mater Res A 2010;94:308-16
70. Liu X, Xie Z, Zhang C, et al. Bioactive borate glass scaffolds: in vitro and in vivo evaluation for use as a drug delivery system in the treatment of bone infection. J Mater Sci Mater Med 2010;21:575-82
71. Shi X, Wang Y, Ren L, et al. Novel mesoporous silica-based antibiotic releasing scaffold for bone repair. Acta Biomater 2009;5:1697-707
72. Sevy JO, Slawson MH, Grainger DW, Brooks AE. Assay method for polymer-controlled antibiotic release from allograft bone to target orthopaedic infections - biomed 2010. Biomed Sci Instrum 2010;46:136-41
73. Jones JR, Ehrenfried LM, Saravanapavan P, Hench LL. Controlling ion release from bioactive glass foam scaffolds with antibacterial properties. J Mater Sci Mater Med 2006;17:989-96 (Pubitemid 44835982)
74. Meseguer-Olmo L, Ros-Nicolas M, Vicente-Ortega V, et al. A bioactive sol-gel glass implant for in vivo gentamicin release. Experimental model in Rabbit. J Orthop Res 2006;24:454-60 (Pubitemid 43773008)
75. Jeon O, Song S, Kang S-W, et al. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(L-lactic-co-glycolic acid) scaffold. Biomaterials 2007;28:2763-71 (Pubitemid 46413347)
76. Moser M, Patterson C. Bone morphogenetic proteins and vascular differentiation: BMPing up vasculogenesis. Thromb Haemost 2005;94:713-18 (Pubitemid 41489229)
77. Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2004;2:141-9 (Pubitemid 39030304)
78. Deckers MM, van Bezooijen RL, van der Horst G, et al. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 2002;143:1545-53 (Pubitemid 34274386)
79. Ripamonti U, van den Heever B, Sampath TK, et al. Complete regeneration of bone in the baboon by recombinant human osteogenic protein-1 (h OP-1, bone morphogenetic protein-7). Growth Factors 1996;13:273
80. Gung YW, Cheng CK, Su CY. A stereomorphologic study of bone matrix apposition in HA-implanted cavities observed with SEM, being prepared by a microvascular cast and freeze-fracture method. Med Eng Phys 2003;25:565-71
81. Lienau J, Schmidt-Bleek K, Peters A, et al. Differential regulation of blood vessel formation between standard and delayed bone healing. J Orthop Res 2009;27:1133-40
82. Li R, Stewart DJ, von Schroeder HP, et al. Effect of cell-based VEGF gene therapy on healing of a segmental bone defect. J Orthop Res 2009;27:8-14
83. Geiger F, Bertram H, Berger I, et al. Vascular endothelial growth factor gene-activated matrix (VEGF165-GAM) enhances osteogenesis and angiogenesis in large segmental bone defects. J Bone Miner Res 2005;20:2028-35 (Pubitemid 41532788)
84. Kempen DH, Lu L, Heijink A, et al. Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. Biomaterials 2009;30:2816-25
85. Cierny G III, Byrd HS, Jones RE. Primary versus delayed soft tissue coverage for severe open tibial fractures. A comparison of results. Clin Orthop Relat Res 1983 Sep;(178):54-63 (Pubitemid 13001142)
86. Fischer MD, Gustilo RB, Varecka TF. The timing of flap coverage, bone-grafting, and intramedullary nailing in patients who have a fracture of the tibial shaft with extensive soft-tissue injury. J Bone Joint Surg Am 1991;73:1316-22
87. Hunt TK. The physiology of wound healing. Ann Emerg Med 1988;17:1265-73 (Pubitemid 19009832)
88. Zilberman M, Elsner JJ. Antibiotic-eluting medical devices for various applications. J Control Release 2008;130:202-15
89. Bowyer G. Debridement of extremity war wounds. J Am Acad Orthop Surg 2006;14:S52-6
90. Thomes B, Murray P, Bouchier-Hayes D. Development of resistant strains of Staphylococcus epidermidis on gentamicin-loaded bone cement in vivo. J Bone Joint Surg Br 2002;84:758-60 (Pubitemid 34846394)
91. Harrison-Balestra C, Cazzaniga AL, Davis SC, Mertz PM. A wound-isolated Pseudomonas aeruginosa grows a biofilm in vitro within 10 hours and is visualized by light microscopy. Dermatol Surg 2003;29:631-5 (Pubitemid 36702450)
92. Anglen JO. Comparison of soap and antibiotic solutions for irrigation of lower-limb open fracture wounds. A prospective, randomized study. J Bone Joint Surg Am 2005;87:1415-22 (Pubitemid 40917739)
93. Pollak AN, Jones AL, Castillo RC, et al. The relationship between time to surgical debridement and incidence of infection after open high-energy lower extremity trauma. J Bone Joint Surg Am 2010;92:7-15
94. Brown KV, Walker JA, Cortez DS, et al. Earlier debridement and antibiotic administration decrease infection. J Surg Orthop Adv 2010;19:18-22
95. Nickel JC, Ruseska I, Wright JB, Costerton JW. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob Agents Chemother 1985;27:619-24 (Pubitemid 15097672)
96. Dunne WM Jr. Bacterial adhesion: seen any good biofilms lately? Clin Microbiol Rev 2002;15:155-66 (Pubitemid 34303761)
97. Percival SL, Hill KE, Malic S, et al. Antimicrobial tolerance and the significance of persister cells in recalcitrant chronic wound biofilms. Wound Repair Regen 2011;19:1-9
98. Tuomanen E, Cozens R, Tosch W, et al. The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol 1986;132:1297-304 (Pubitemid 16115638)
99. Dunne WM Jr, Mason EO Jr, Kaplan SL. Diffusion of rifampin and vancomycin through a Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother 1993;37:2522-6 (Pubitemid 23357840)
100. Veeh RH, Shirtliff ME, Petik JR, et al. Detection of Staphylococcus aureus biofilm on tampons and menses components. J Infect Dis 2003;188:519-30 (Pubitemid 37011803)
101. Cordero J, Munuera L, Folgueira MD. Influence of bacterial strains on bone infection. J Orthop Res 1996;14:663-7 (Pubitemid 26278106)
102. Petty W, Spanier S, Shuster JJ, Silverthorne C. The influence of skeletal implants on incidence of infection. Experiments in a canine model. J Bone Joint Surg Am 1985;67:1236-44 (Pubitemid 16222967)
103. Wenke JC, Owens BD, Svoboda SJ, Brooks DE. Effectiveness of commercially-available antibiotic- impregnated implants. J Bone Joint Surg Br 2006;88:1102-4
104. Osterman P, Seligson D, Henry S. Local antibiotic therapy for severe open fractures: a review of 1085 consecutive cases. J Bone Joint Surg Br 1995;77:93-7
105. Moehring HD, Gravel C, Chapman MW, Olson SA. Comparison of antibiotic beads and intravenous antibiotics in open fractures. Clin Orthop Relat Res 2000 Mar;(372):254-61 (Pubitemid 30159454)
106. Ostermann PA, Seligson D, Henry SL. Local antibiotic therapy for severe open fractures. A review of 1085 consecutive cases. J Bone Joint Surg Br 1995;77:93-7
107. Mc Laren AC Alternative materials to acrylic bone cement for delivery of depot antibiotics in orthopaedic infections. Clin Orthop Relat Res 2004 Oct;(427):101-16
108. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002;84-A:2123-34 (Pubitemid 35417689)
109. Ong KL, Villarraga ML, Lau E, et al. Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine 2010;35:1794-800
110. Epstein NE. Pros, cons, and costs of INFUSE in spinal surgery. Surg Neurol Int 2011;2:10
111. Chen XQ, Kidder LS, Lew WD. Osteogenic protein-1 induced bone formation in an infected segmental defect in the rat femur. J Orthop Res 2002;20:142-50
112. Chen XQ, Tsukayama DT, Kidder LS, et al. Characterization of a chronic infection in an internally-stabilized segmental defect in the rat femur. J Orthop Res 2005;23:816-23 (Pubitemid 40960033)
113. Winkler H, Kaudela K, Stoiber A, Menschik F. Bone grafts impregnated with antibiotics as a tool for treating infected implants in orthopedic surgery - one stage revision results. Cell Tissue Bank 2006;7:319-23 (Pubitemid 44724555)
114. Rathbone CR, Cross JD, Brown KV, et al. Effect of various concentrations of antibiotics on osteogenic cell viability and activity. J Orthop Res 2011;29:1070-4
115. Rogers-Foy J, Powers D, Brosnan D, et al. Hydroxyapatite composites designed for antibiotic drug delivery and bone reconstruction: a caprine model. J Invest Surg 1999;12:263-75 (Pubitemid 29515592)
116. Suzuki A, Terai H, Toyoda H, et al. A biodegradable delivery system for antibiotics and recombinant human bone morphogenetic protein-2: a potential treatment for infected bone defects. J Orthop Res 2006;24(3):327-32 (Pubitemid 43772992)
117. Zhang X, Jia W, Gu Y, et al. Teicoplanin-loaded borate bioactive glass implants for treating chronic bone infection in a rabbit tibia osteomyelitis model. Biomaterials 2010;31:5865-74
118. Edin ML, Miclau T, Lester GE, et al. Effect of cefazolin and vancomycin on osteoblasts in vitro. Clin Orthop Relat Res 1996 Dec;(333):245-51 (Pubitemid 26428036)
119. Antoci V, Adams CS, Hickok NJ, et al. Antibiotics for local delivery systems cause skeletal cell toxicity in vitro. Clin Orthop Relat Res 2007;462:200-6 (Pubitemid 47367864)
120. Haleem AA, Rouse MS, Lewallen DG, et al. Gentamicin and vancomycin do not impair experimental fracture healing. Clin Orthop Relat Res 2004 Oct;(427):22-4 (Pubitemid 39362825)
121. Li B, Brown KV, Wenke JC, Guelcher SA. Sustained release of vancomycin from polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental defect model. J Control Release 2010;145:221-30
122. Swanson PA II, Kumar A, Samarin S, et al. Enteric commensal bacteria potentiate epithelial restitution via reactive oxygen species-mediated inactivation of focal adhesion kinase phosphatases. Proc Natl Acad Sci USA 2011;108:8803-8
123. Dumas JE, Zienkiewicz K, Tanner SA, et al. Synthesis and characterization of an injectable allograft bone/polymer composite bone void filler with tunable mechanical properties. Tissue Eng Part A 2010;16:2505-18